Oculis (NASDAQ:OCS) Given New $40.00 Price Target at Stifel Nicolaus

Oculis (NASDAQ:OCS) had its price objective hoisted by Stifel Nicolaus from $35.00 to $40.00 in a research note released on Friday morning, MarketBeat.com reports. Stifel Nicolaus currently has a buy rating on the stock.

Other research analysts have also issued reports about the stock. JPMorgan Chase & Co. initiated coverage on shares of Oculis in a research report on Friday. They set an “overweight” rating and a $38.00 target price on the stock. Bank of America lowered their price target on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Wednesday, October 8th. Wall Street Zen upgraded Oculis from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Lifesci Capital assumed coverage on Oculis in a research report on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $41.50.

Oculis Trading Up 9.1%

Shares of OCS stock opened at $21.25 on Friday. The business’s fifty day moving average price is $20.10 and its 200 day moving average price is $18.87. The firm has a market capitalization of $1.11 billion, a PE ratio of -8.43 and a beta of 0.32. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47. Oculis has a 1-year low of $14.00 and a 1-year high of $23.08.

Oculis (NASDAQ:OCS) last issued its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.10. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. As a group, sell-side analysts forecast that Oculis will post -2.09 EPS for the current fiscal year.

Institutional Trading of Oculis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bosun Asset Management LLC purchased a new position in Oculis in the 2nd quarter valued at about $378,000. Marshall Wace LLP acquired a new position in shares of Oculis in the second quarter valued at approximately $393,000. Geode Capital Management LLC lifted its stake in shares of Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after buying an additional 6,384 shares during the period. Bank of America Corp DE boosted its position in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after acquiring an additional 878 shares during the last quarter. Finally, Woodline Partners LP grew its stake in Oculis by 65.8% in the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after acquiring an additional 33,265 shares during the period. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.